MD1629G2 - Method of salmonellosis prevention - Google Patents
Method of salmonellosis preventionInfo
- Publication number
- MD1629G2 MD1629G2 MDA20000079A MD20000079A MD1629G2 MD 1629 G2 MD1629 G2 MD 1629G2 MD A20000079 A MDA20000079 A MD A20000079A MD 20000079 A MD20000079 A MD 20000079A MD 1629 G2 MD1629 G2 MD 1629G2
- Authority
- MD
- Moldova
- Prior art keywords
- salmonellosis
- enterosorbent
- prevention
- administration
- invention consists
- Prior art date
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Farming Of Fish And Shellfish (AREA)
Abstract
The invention relates to medicine, particularly to a method of salmonellosis prevention.Summary of the invention consists in administration of enterosorbent obtained of the fruit stone coat, which is effected the first day following the infection in a dose of 400 mg/kg of chemically activated enterosorbent, with a dispersion degree of 0,25…1,0 mm and the pore total volume of 0,76…1,24 cm3/g.The result of the invention consists in diminution of salmonellosis toxic manifestations after administration of enterosorbent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20000079A MD1629G2 (en) | 2000-04-26 | 2000-04-26 | Method of salmonellosis prevention |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20000079A MD1629G2 (en) | 2000-04-26 | 2000-04-26 | Method of salmonellosis prevention |
Publications (2)
Publication Number | Publication Date |
---|---|
MD1629F1 MD1629F1 (en) | 2001-03-31 |
MD1629G2 true MD1629G2 (en) | 2001-09-30 |
Family
ID=19739590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20000079A MD1629G2 (en) | 2000-04-26 | 2000-04-26 | Method of salmonellosis prevention |
Country Status (1)
Country | Link |
---|---|
MD (1) | MD1629G2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD587C2 (en) * | 1995-06-12 | 1997-03-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Carbon adsorption mean "Carbasan" |
-
2000
- 2000-04-26 MD MDA20000079A patent/MD1629G2/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD587C2 (en) * | 1995-06-12 | 1997-03-31 | Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова | Carbon adsorption mean "Carbasan" |
Non-Patent Citations (1)
Title |
---|
Л.Г., Григорьев А.В., Знаменский В.А., Ковальчук В.К., Алексеенко Е.П., Экспериментальное изучение активности энтеросорбентов при сальмонелезе, * |
Also Published As
Publication number | Publication date |
---|---|
MD1629F1 (en) | 2001-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG52240A1 (en) | The use of cetrorelix and other nona-and decapeptides in the preparation of a medicament for combating aids and for growth stimulation | |
WO2001078698A3 (en) | Use of ngf-antagonists for the prevention or treatment of chronic visceral pain | |
EP1600168A3 (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder | |
NO993520D0 (en) | Dosage forms and methods for improving erectile dysfunction | |
AU2003274071A1 (en) | Dosage form that is safeguarded from abuse | |
WO2002089778A3 (en) | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
WO2001074365A3 (en) | An efficacious dosage regimen of galantamine that reduces side effects | |
AP2049A (en) | Medicament containing activated antithrombin III | |
AU7862401A (en) | Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer | |
WO2001076601A3 (en) | Pharmaceutical compositions comprising salmeterol and ipratropium | |
MD1629G2 (en) | Method of salmonellosis prevention | |
YU29804A (en) | USE OF gp 130 ACTIVATORS IN DIABETIC NEUROPATHY | |
EP1806144A3 (en) | Use of SARP-1 for the treatment and/or prevention of scleroderma | |
HK1075390A1 (en) | Citalopram for the treatment of elevated blood pressure | |
NZ533627A (en) | Remedies and/or preventatives for neurodegenerative diseases using VIP or PACAP peptides | |
AU2002225097A1 (en) | Novel therapeutic use of a thienylcyclohexylamine derivative | |
MXPA05011249A (en) | Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse. | |
MXPA01008491A (en) | Therapeutically active mixture of substances containing s-acetylglutathione and aciclovir. | |
MD1609G2 (en) | Method of the recidivating chronic aphthous stomatitis treatment | |
MD1611F1 (en) | Antibacterial and antifungal remedy | |
MD1580G2 (en) | Antimutagenis agent | |
MD1919F2 (en) | Medicinal remedy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
MM4A | Patent for invention definitely lapsed due to non-payment of fees |